The Design and Rationale of the Trail1 Trial: A Randomized Double-Blind Phase 2 Clinical Trial of Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung Disease.
Joshua J Solomon
Sonye K Danoff
Hilary J Goldberg
Felix Woodhead
Martin Kolb
Daniel C Chambers
Donna DiFranco
Cathy Spino
Shana Haynes-Harp
Shelley Hurwitz
Elizabeth B Peters
Paul F Dellaripa
Ivan O Rosas
on behalf of the Trail Network
10.6084/m9.figshare.9741716.v2
https://adisjournals.figshare.com/articles/figure/The_Design_and_Rationale_of_the_Trail1_Trial_A_Randomized_Double-Blind_Phase_2_Clinical_Trial_of_Pirfenidone_in_Rheumatoid_Arthritis-Associated_Interstitial_Lung_Disease_/9741716
<p><strong>Provide enhanced digital features for this article</strong><br></p><p>
If you are an author of this publication and would like to provide additional
enhanced digital features for your article then please contact <u>adisrapidplus@springer.com</u>.<br>
<br>
The journal offers a range of additional features designed to increase
visibility and readership. All features will be thoroughly peer reviewed to
ensure the content is of the highest scientific standard and all features are
marked as ‘peer reviewed’ to ensure readers are aware that the content has been
reviewed to the same level as the articles they are being presented alongside.
Moreover, all sponsorship and disclosure information is included to provide
complete transparency and adherence to good publication practices. This ensures
that however the content is reached the reader has a full understanding of its
origin. No fees are charged for hosting additional open access content.<br>
<br>
Other enhanced features include, but are not limited to:<br>
• Slide decks<br>
• Videos and animations<br>
• Audio abstracts<br>
• Audio slides</p>
2019-11-18 11:12:31
Arthritis
Interstitial
Fibrosis
Pirfenidone
Pulmonary
Rheumatoid